The nice
people at Transfusion News sent their update today. Much of this is focussing
on what happens to the samples that we send to the reference lab… but it is as
well to know what the are getting up to…
RBC Transfusions and Alloimmunization in Patients Taking Daratumumab
 | | October 12, 2021 | | Daratumumab
(Dara), an anti-CD38 monoclonal antibody, was approved by the U.S. Food
and Drug Administration (FDA) in 2015 for use in patients with
hematologic malignancies. Compared to normal lymphoid and myeloid cells,
multiple myeloma cells express high levels of CD38 making these
cancerous cells targets for Dara. Dara, however, also binds to RBCs
which express CD38, thus interfering with antibody screens, antibody
identification, and other serological tests. [Read More] |
|
 | | In
this new Transfusion Science Webinar, Shane Grimsley, Manager of the
Red Cell Reference Laboratory at the International Blood Group Reference
Laboratory (IBGRL), based in Bristol, UK, will show us how complex
cases can be resolved and in particular, will discuss the many tools
that are available for the resolution of complex antibody
investigations. [Register Now] |
|
 | | October 13, 2021 | BBGuy Podcast | | CE
episode! When red cell alloantibodies are unpredictable, the monocyte
monolayer assay can clear things right up! Sandy Nance explains this
very useful test. [Listen Now] |
|
|
| October 6, 2021 |
| In
order to tease apart whether fear and anxiety in first-time blood
donors actually led to fewer return donations, researchers followed 1479
first-time blood donors (67.9% female; mean age, 19.3 years)
longitudinally over 14 months. First-time donors were invited to
complete a survey one week following their first blood donation and
again six weeks later. [Register Now] |
No comments:
Post a Comment